Cytokinetics Incorporated (CYTK) Financial Statements (2026 and earlier)

Company Profile

Business Address 350 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,221,100655,400829,300623,700501,000267,800
Cash and cash equivalent94,857113,02465,582112,66682,98536,433
Short-term investments981,157501,800716,995358,972381,075189,679
Other undisclosed cash, cash equivalents, and short-term investments145,08640,57646,723152,06236,94041,688
Receivables16,6501,28314751,8194,4205,163
Other undisclosed current assets(129,810)(28,632)(34,261)(139,847)(31,199)(39,211)
Total current assets:1,107,940628,051795,186535,672474,221233,752
Noncurrent Assets
Operating lease, right-of-use asset75,15878,98782,73773,138  
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization65,81568,74880,45373,27113,3464,530
Long-term investments and receivables145,05540,53446,708152,050  
Long-term investments145,05540,53446,708152,050  
Other noncurrent assets7,7057,9969,6917,188  
Other undisclosed noncurrent assets     46,23651,532
Total noncurrent assets:293,733196,265219,589305,64759,58256,062
TOTAL ASSETS:1,401,673824,3161,014,775841,319533,803289,814
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities75,69264,14869,70755,45727,36520,283
Accounts payable20,36921,50725,61121,0878,0508,160
Accrued liabilities55,32342,64144,09634,37019,31512,123
Deferred revenue52,370     
Debt11,52010,080   4,616
Derivative instruments and hedges, liabilities11,300     
Other liabilities9,81410,5592,0811,5401,0491,124
Other undisclosed current liabilities18,97817,89112,82914,8632,785 
Total current liabilities:179,674102,67884,61771,86031,19926,023
Noncurrent Liabilities
Long-term debt and lease obligation93,22758,38463,810159,59646,20947,247
Long-term debt, excluding current maturities93,22758,38463,81047,36746,20945,052
Liabilities, other than long-term debt112,582120,613127,93991,45787,000 
Deferred revenue    87,00087,000 
Other liabilities  1861,0444,457  
Operating lease, liability112,582120,427126,895112,229 2,195
Other undisclosed noncurrent liabilities1,151,562928,964846,309274,543256,012227,481
Total noncurrent liabilities:1,357,3711,107,9611,038,058525,596389,221274,728
Total liabilities:1,537,0451,210,6391,122,675597,456420,420300,751
Equity
Equity, attributable to parent(135,372)(386,323)(107,900)243,863113,383(10,937)
Common stock11810294847059
Additional paid in capital2,563,8761,725,8231,481,5901,452,2681,105,470853,341
Accumulated other comprehensive income (loss)2,398(10)(3,590)(869)149679
Accumulated deficit(2,701,764)(2,112,238)(1,585,994)(1,207,620)(992,306)(865,016)
Total equity:(135,372)(386,323)(107,900)243,863113,383(10,937)
TOTAL LIABILITIES AND EQUITY:1,401,673824,3161,014,775841,319533,803289,814

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues18,4747,53094,58870,42855,82826,868
Gross profit:18,4747,53094,58870,42855,82826,868
Operating expenses(554,722)(503,735)(418,790)(256,741)(149,771)(125,735)
Operating loss:(536,248)(496,205)(324,202)(186,313)(93,943)(98,867)
Nonoperating income51,53427,62911,3423315,3294,535
Investment income, nonoperating   11,4001,0005,3004,500
Interest and debt expense  (28,306)(44,353)(16,440)(15,963)(6,623)
Loss from continuing operations:(484,714)(496,882)(357,213)(202,422)(104,577)(100,955)
Loss before gain (loss) on sale of properties:(202,422)(104,577)(100,955)
Other undisclosed net loss(104,812)(29,362)(31,742)(12,892)(22,713)(20,737)
Net loss available to common stockholders, diluted:(589,526)(526,244)(388,955)(215,314)(127,290)(121,692)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(589,526)(526,244)(388,955)(215,314)(127,290)(121,692)
Other comprehensive income (loss) 2,4083,580(2,721)(1,018)(530)179
Comprehensive loss:(587,118)(522,664)(391,676)(216,332)(127,820)(121,513)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(587,118)(522,664)(391,676)(216,332)(127,820)(121,513)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: